Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 6:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 7,076 matching trials from the live ClinicalTrials.gov search.
Conditions
Left Ventricular Diastolic Dysfunction
Interventions
BNP (nesiritide), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Conditions
Racial Disparities, Blood Pressure, Cardiovascular Risk Factor, Renal Function
Interventions
MitoQ
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
19 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Auburn, Alabama
Conditions
Rheumatoid Arthritis
Interventions
PTC844, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chandler, Arizona • Flagstaff, Arizona • Phoenix, Arizona + 10 more
Conditions
Hypereosinophilic Syndrome
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
Interventions
Sulforaphane (Avmacol Extra Strength), Placebo
Drug · Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Chula Vista, California • Overland Park, Kansas • Louisville, Kentucky
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions
Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bannockburn, Illinois
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Conditions
Lumbar Spinal Stenosis, Thoracic Spinal Stenosis
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
69
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arkansas + 62 more
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Conditions
Lung Injury, Acute
Interventions
SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 3 more
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Conditions
Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
Conditions
Covid19
Interventions
Bardoxolone Methyl, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Springfield, Illinois • Brooklyn, New York • Elmhurst, New York + 2 more
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Darcy Krueger
Other
Eligibility
1 Day to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 5 more
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Conditions
Asthma
Interventions
Oglemilast, Placebo then Oglemilast
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alopecia Areata
Interventions
JNJ-64304500, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
Conditions
Muscle Spasticity
Interventions
XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Downey, California • Gilroy, California • Pasadena, California + 8 more